Association between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Jin Hwa | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Baek, Sun Kyung | - |
dc.contributor.author | Kim, Jong Gwang | - |
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Sohn, Seung Kook | - |
dc.contributor.author | Kang, Mi Yeon | - |
dc.contributor.author | Lee, Sang-Cheol | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.date.accessioned | 2022-06-21T01:50:08Z | - |
dc.date.available | 2022-06-21T01:50:08Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1837-9664 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21081 | - |
dc.description.abstract | Background: Population-based analyses of the treatment outcomes of colorectal cancer (CRC) in Asian countries are limited. Therefore, we conducted a nationwide study to assess the relationship between the timing and duration of adjuvant chemotherapy (AC) and survival in patients with CRC in South Korea. Methods: Data on AC from the Health Insurance Review and Assessment Service Database (HIRA) were analyzed, and the survival of patients who underwent curative-intent surgical resection for CRC between 2011 and 2014 was investigated. Results: From the HIRA data, 45,992 patients with stage II-III CRC were identified. Chemotherapy regimens were administered as follows: 10,640 (23.3%) received 5-fluorouracil and leucovorin/capecitabine (FL/CAP), 13,083 (28.7%) received FUCAP plus oxaliplatin (FOLFOX/CAPDX), 299 (0.7%) received uracil and tegafur/doxifluridine (UFT/D), and 21,570 (47.3%) underwent surgery alone. Patients who did not receive AC had worse survival than those who received AC in both the colon and rectum groups (HR, 1.96, 95% CI, 1.85-2.07 and HR, 2.18, 95% CI, 2.01-2.37, respectively). Regarding patients with stage II-III CRC, AC initiation >= 2 months after surgery was associated with a significant decrease in overall survival (OS) (FUCAP: HR, 1.82; 95% CI, 1.53-2.17 and FOLFOX/CAPDX: HR, 2.92; 95% CI, 2.47-3.45); however, the effects of UFT/D regimens were not statistically significant. For patients with stage II-III colon cancer, AC <3 months had lower OS (FL/CAP: HR, 3.72, 95% CI, 2.80-4.94; FOLFOX/CAPDX: HR, 2.15, 95% CI, 1.87-2.47; and UFT/D: HR, 1.74, 95% CI, 0.56-5.41). In terms of patients with stage II-III rectal cancer, AC <3 months, regardless of chemotherapy regimens, had a significant lower survival (FUCAP: HR, 1.91, 95% CI, 1.66-2.20; FOLFOX/CAPDX: HR, 2.20, 95% CI, 1.75-2.77; and UFT/D: HR, 3.71, 95% CI, 1.45-9.44). Conclusions: Postoperative time to initiation and duration of AC were associated with survival. Based on our results, initiating AC within 2 months after surgery and administering AC for >3 months can potentially have an OS benefit in patients with stage II-III CRC. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Ivyspring International Publisher | - |
dc.title | Association between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database | - |
dc.type | Article | - |
dc.publisher.location | 호주 | - |
dc.identifier.doi | 10.7150/jca.71141 | - |
dc.identifier.scopusid | 2-s2.0-85130183347 | - |
dc.identifier.wosid | 000795768400008 | - |
dc.identifier.bibliographicCitation | Journal of Cancer, v.13, no.8, pp 2440 - 2446 | - |
dc.citation.title | Journal of Cancer | - |
dc.citation.volume | 13 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2440 | - |
dc.citation.endPage | 2446 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | III COLON-CANCER | - |
dc.subject.keywordPlus | STAGE-II | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | INITIATION | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordAuthor | colorectal cancer | - |
dc.subject.keywordAuthor | adjuvant chemotherapy | - |
dc.subject.keywordAuthor | timing | - |
dc.subject.keywordAuthor | duration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.